Pharmacology Quiz: Hypertriglyceridemia Agents
20 questions · exam conditions
0:00
Hypertriglyceridemia AgentsQuestion 1 of 20

A patient with mixed dyslipidemia is treated with fenofibrate. In addition to expected decreases in triglycerides and increases in HDL-C, which other laboratory parameter is most likely to show a sustained, reversible increase directly attributable to the pharmacological action of the drug?

Alanine aminotransferase (ALT)
Serum creatinine
Hemoglobin A1c
Thyroid-stimulating hormone (TSH)
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Hypertriglyceridemia Agents

Practice Hypertriglyceridemia Agents in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Hypertriglyceridemia Agents, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A patient with mixed dyslipidemia is treated with fenofibrate. In addition to expected decreases in triglycerides and increases in HDL-C, which other laboratory parameter is most likely to show a sustained, reversible increase directly attributable to the pharmacological action of the drug?

  1. Alanine aminotransferase (ALT)
  2. Serum creatinine (correct answer)
  3. Hemoglobin A1c
  4. Thyroid-stimulating hormone (TSH)
Explanation: Fibrates, particularly fenofibrate, are known to cause a modest, dose-dependent, and reversible increase in serum creatinine. This is not typically indicative of true kidney damage but is thought to be a hemodynamic effect related to the inhibition of creatinine's tubular secretion or altered production. This effect is important to recognize to avoid misinterpretation as worsening renal function. While LFT elevations can occur, they are usually transient or indicative of hepatotoxicity, not a sustained, expected finding. Fibrates do not typically affect HbA1c or TSH.

Question 2

Apolipoprotein C-III (ApoC-III) is a key regulator of triglyceride metabolism and an inhibitory protein for lipoprotein lipase (LPL). Activation of PPAR-α by fibrates leads to a reduction in hepatic ApoC-III synthesis. What is the direct functional consequence of this reduction in ApoC-III?

  1. Increased hepatic uptake of chylomicron remnants.
  2. Decreased affinity of LDL particles for the LDL receptor.
  3. Disinhibition of lipoprotein lipase, leading to enhanced VLDL catabolism. (correct answer)
  4. Reduced cholesterol ester transfer from HDL to VLDL.
Explanation: ApoC-III is a potent inhibitor of lipoprotein lipase (LPL), the primary enzyme responsible for hydrolyzing triglycerides in VLDL and chylomicrons. By activating PPAR-α, fibrates suppress the gene expression of ApoC-III. The resulting decrease in circulating ApoC-III levels relieves the inhibition on LPL, leading to increased LPL activity and more efficient catabolism of triglyceride-rich lipoproteins. This is a significant, albeit indirect, mechanism by which fibrates lower plasma triglyceride levels.

Question 3

A 65-year-old patient with type 2 diabetes and an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73m² requires therapy for severe hypertriglyceridemia. If a fibrate is chosen, which of the following represents the most appropriate course of action?

  1. Initiate gemfibrozil at the standard dose as it is hepatically metabolized.
  2. Initiate fenofibrate at a reduced dose with close monitoring of renal function. (correct answer)
  3. Avoid all fibrates as they are contraindicated in any stage of chronic kidney disease.
  4. Prescribe fenofibrate at the standard dose but monitor serum creatinine monthly.
Explanation: Fibrates and their active metabolites are primarily eliminated by the kidneys. In patients with moderate chronic kidney disease (CKD), such as an eGFR of 45 mL/min/1.73m², fibrate accumulation can occur, increasing the risk of adverse effects, particularly myopathy. Fenofibrate can be used cautiously in patients with an eGFR between 30 and 59 mL/min/1.73m², but requires a dose reduction and careful monitoring of renal function. Gemfibrozil is generally not recommended in patients with moderate to severe CKD.

Question 4

A patient with severe hypertriglyceridemia (triglycerides > 1000 mg/dL) is started on fenofibrate. After 3 months of therapy, their triglycerides decrease to 300 mg/dL and HDL-C increases from 22 mg/dL to 30 mg/dL. However, their calculated LDL-C has unexpectedly increased from 65 mg/dL to 105 mg/dL.

Which of the following mechanisms best accounts for the observed increase in LDL-C in this patient?

  1. Fibrate-induced downregulation of hepatic LDL receptors.
  2. Increased hepatic synthesis of ApoB-100 containing lipoproteins.
  3. Enhanced conversion of VLDL particles to LDL particles via lipoprotein lipase. (correct answer)
  4. Decreased cholesterol esterification by lecithin-cholesterol acyltransferase (LCAT).
Explanation: Fibrates, via PPAR-α activation, increase the synthesis of lipoprotein lipase (LPL). LPL catabolizes triglyceride-rich lipoproteins like VLDL. In patients with very high baseline triglycerides, the rapid breakdown of a large number of VLDL particles leads to an increased production of VLDL remnants and subsequently LDL particles. This flux through the lipolytic cascade can result in a paradoxical increase in LDL-C, even as triglyceride levels fall dramatically.

Question 5

A patient is considering using an over-the-counter fish oil supplement instead of a prescription omega-3 fatty acid product like icosapent ethyl for managing triglyceride levels of 600 mg/dL. Which of the following represents the most significant clinical limitation of using non-prescription supplements for this indication?

  1. Non-prescription supplements contain only the less effective DHA form of omega-3.
  2. Supplements are typically enteric-coated, which reduces the bioavailability of EPA and DHA.
  3. Over-the-counter products are more likely to cause myopathy when combined with statins.
  4. The lower concentration of active ingredients requires ingesting a large, often impractical number of capsules. (correct answer)
Explanation: When you encounter questions comparing prescription omega-3 products to over-the-counter supplements, focus on the practical differences that affect clinical efficacy rather than theoretical pharmacological distinctions. The most significant limitation of OTC fish oil supplements is their low concentration of active omega-3 fatty acids. Prescription products like icosapent ethyl contain highly concentrated EPA (typically 840-1000mg per capsule), while most OTC supplements contain only 300-500mg of combined EPA and DHA per capsule. For a patient with triglycerides of 600 mg/dL, effective treatment typically requires 2-4 grams of omega-3s daily. This means taking 8-12 supplement capsules daily versus 2-4 prescription capsules - a difference that significantly impacts patient adherence and tolerability. Option A is incorrect because many OTC supplements contain both EPA and DHA, and DHA isn't inherently "less effective" - it simply has different therapeutic targets than EPA. Option B misrepresents supplement formulations; enteric coating actually improves tolerability and doesn't reduce bioavailability of omega-3s. Option C incorrectly suggests supplements have higher myopathy risk with statins - this interaction profile is similar between prescription and OTC omega-3 products and is generally minimal. Remember this pattern: when comparing prescription versus OTC formulations of the same drug class, the key clinical difference is usually potency and standardization, not fundamental safety or mechanism differences. High-dose prescription omega-3s exist specifically because achieving therapeutic levels with standard supplements requires impractically large pill burdens.

Question 6

A patient taking high-dose omega-3-acid ethyl esters is scheduled for an elective knee replacement surgery in two weeks. What is the most appropriate recommendation regarding this medication prior to the procedure?

  1. Continue the medication as it has no effect on hemostasis.
  2. Increase the dose to reduce perioperative inflammatory responses.
  3. Discontinue the medication 5-7 days before surgery due to increased bleeding risk. (correct answer)
  4. Switch to a low-dose aspirin for superior antiplatelet effect.
Explanation: High doses of omega-3 fatty acids (typically >3 g/day) can inhibit platelet aggregation and prolong bleeding time. This effect is thought to be due to competition with arachidonic acid in the cyclooxygenase and lipoxygenase pathways, leading to the formation of less potent thromboxane A3 and prostaglandin I3. To minimize the risk of perioperative bleeding, it is often recommended to discontinue high-dose omega-3 supplements 5-7 days before elective surgery, allowing time for platelet function to normalize.

Question 7

While both fibrates and omega-3 fatty acids are used to treat hypertriglyceridemia, their effects on other lipid parameters differ. A significant increase in which of the following is more characteristic of fibrate therapy compared to high-dose omega-3 fatty acid therapy?

  1. LDL particle number
  2. VLDL triglyceride content
  3. Lipoprotein(a) concentration
  4. HDL-C concentration (correct answer)
Explanation: When comparing lipid-lowering therapies, you need to understand that different drug classes have distinct mechanisms and therefore produce different patterns of lipid changes, even when treating the same condition. Fibrates primarily work by activating PPAR-α (peroxisome proliferator-activated receptor alpha), which has multiple effects on lipid metabolism. Most notably, they significantly increase HDL-C production by upregulating apolipoprotein A-I synthesis and enhancing reverse cholesterol transport. This HDL-C elevation is one of fibrates' most characteristic and clinically significant effects, often increasing levels by 15-25%. High-dose omega-3 fatty acids (like prescription icosapent ethyl) primarily reduce hepatic VLDL production and enhance triglyceride clearance, but they have minimal impact on HDL-C levels. Therefore, answer D is correct - HDL-C concentration increase is much more characteristic of fibrate therapy. Let's examine why the other options are incorrect: A) LDL particle number actually tends to decrease or remain unchanged with fibrates, and omega-3s have variable effects on LDL particles. B) VLDL triglyceride content decreases with both therapies since both target triglyceride reduction - this isn't a distinguishing feature. C) Lipoprotein(a) concentrations are not significantly affected by either therapy and aren't a primary target of triglyceride-lowering treatments. Remember this key distinction: fibrates are "HDL raisers" in addition to triglyceride lowerers, while omega-3s are more selective triglyceride reducers. This pattern frequently appears on pharmacology exams when comparing lipid therapies.

Question 8

A patient with familial hypertriglyceridemia is prescribed icosapent ethyl. A proposed mechanism for this drug's anti-inflammatory and plaque stabilization effects, beyond lipid lowering, involves altering the composition of cell membranes. How does incorporation of eicosapentaenoic acid (EPA) into cell membranes achieve this effect?

  1. It increases membrane fluidity, preventing the aggregation of pro-inflammatory receptors.
  2. It displaces arachidonic acid, leading to the production of less inflammatory eicosanoids. (correct answer)
  3. It directly binds to and inactivates Toll-like receptors on macrophage surfaces.
  4. It chelates intracellular calcium, preventing the activation of phospholipase A2.
Explanation: Eicosapentaenoic acid (EPA) competes with arachidonic acid (AA), an omega-6 fatty acid, for incorporation into cell membrane phospholipids. When inflammatory stimuli activate phospholipase A2, it releases these fatty acids. AA is metabolized into highly pro-inflammatory eicosanoids (e.g., prostaglandin E2, thromboxane A2, leukotriene B4). In contrast, EPA is metabolized into eicosanoids (e.g., prostaglandin E3, thromboxane A3, leukotriene B5) that are significantly less inflammatory or even anti-inflammatory. This shift in the balance of eicosanoid production is a key mechanism for the pleiotropic effects of EPA.

Question 9

A patient taking atorvastatin and fenofibrate develops severe muscle pain and weakness. Laboratory tests show a markedly elevated creatine kinase (CK) level. The fenofibrate is discontinued, but the patient's symptoms persist. Which pharmacokinetic property of fenofibrate is most likely contributing to the prolonged myopathy?

  1. Fenofibric acid, the active metabolite, has a long elimination half-life of approximately 20 hours. (correct answer)
  2. Fenofibrate induces its own metabolism, leading to accumulation of a toxic intermediate.
  3. Fenofibrate is sequestered in muscle tissue and leaches out slowly over several days.
  4. The drug causes irreversible inhibition of enzymes involved in statin metabolism.
Explanation: Fenofibrate is a prodrug that is rapidly hydrolyzed to its active metabolite, fenofibric acid. Fenofibric acid is responsible for the drug's therapeutic and toxic effects. It has a relatively long elimination half-life of about 20 hours. In the context of drug-induced myopathy, this means that even after discontinuing the drug, clinically significant concentrations can persist in the body for several days, leading to a delayed resolution of symptoms. The half-life can be even longer in patients with renal impairment.

Question 10

The activation of peroxisome proliferator-activated receptor alpha (PPAR-α) by a fibrate initiates a cascade of transcriptional changes. Which of the following represents a direct transcriptional upregulation by PPAR-α activation that contributes to triglyceride lowering?

  1. Increased expression of fatty acid transport protein and acyl-CoA synthetase genes. (correct answer)
  2. Decreased expression of the gene encoding for the LDL receptor.
  3. Increased expression of the gene encoding for HMG-CoA reductase.
  4. Decreased expression of genes for HDL-associated apolipoproteins A-I and A-II.
Explanation: PPAR-α is a nuclear receptor that acts as a transcription factor for genes involved in lipid metabolism. Upon activation by fibrates, it upregulates the expression of genes involved in fatty acid uptake and oxidation. This includes genes for fatty acid transport protein and acyl-CoA synthetase, which facilitates the entry of fatty acids into cells and their activation for β-oxidation in mitochondria. This increased fatty acid catabolism reduces the substrate available for triglyceride synthesis in the liver. PPAR-α activation increases, not decreases, expression of ApoA-I and ApoA-II, contributing to higher HDL levels.

Question 11

A patient taking gemfibrozil for severe hypertriglyceridemia for the past year presents with recurrent episodes of severe right upper quadrant abdominal pain, particularly after fatty meals. An ultrasound confirms the presence of gallstones. What is the primary mechanism by which gemfibrozil contributed to this condition?

  1. Inhibition of bile acid synthesis, leading to supersaturation of bile with cholesterol.
  2. Increased biliary secretion of cholesterol, which alters the cholesterol-to-bile salt ratio. (correct answer)
  3. Drug-induced cholestasis leading to decreased bile flow and sludge formation.
  4. Enhanced intestinal absorption of dietary cholesterol, increasing its hepatic pool.
Explanation: Fibrates, including gemfibrozil, increase the risk of cholelithiasis (gallstones). The mechanism involves the upregulation of cholesterol transporters in the liver, which leads to an increased secretion of cholesterol into the bile. This supersaturates the bile with cholesterol, exceeding the solubilizing capacity of bile salts and phospholipids, and promoting the formation of cholesterol crystals and stones.

Question 12

A 62-year-old female with persistent hypertriglyceridemia despite lifestyle modifications is prescribed a high-dose omega-3 fatty acid product. Two months later, her triglycerides have decreased by 30%, but her LDL-C has increased by 15%. This LDL-C increase is most likely attributable to which component of the prescribed medication?

  1. Eicosapentaenoic acid (EPA), which inhibits diacylglycerol O-acyltransferase.
  2. Docosahexaenoic acid (DHA), which may reduce LDL receptor activity. (correct answer)
  3. Alpha-linolenic acid (ALA), a plant-based precursor to EPA and DHA.
  4. Gamma-linolenic acid (GLA), an omega-6 fatty acid found in some oils.
Explanation: Omega-3 fatty acid products containing both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) can sometimes cause an increase in LDL-C levels. This effect is primarily attributed to DHA. While the exact mechanism is not fully elucidated, it may involve a reduction in LDL receptor activity or an increase in the conversion of VLDL to larger, more buoyant LDL particles. Formulations containing only EPA (icosapent ethyl) do not typically raise LDL-C and have been shown to reduce cardiovascular events in high-risk patients.

Question 13

Icosapent ethyl, a prescription omega-3 fatty acid formulation, has been shown to reduce cardiovascular events in high-risk patients with elevated triglycerides. Its therapeutic effect is mediated through multiple mechanisms. Which of the following is considered a primary mechanism for the triglyceride-lowering effect of icosapent ethyl?

  1. Upregulation of hepatic HMG-CoA reductase activity.
  2. Inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT). (correct answer)
  3. Increased expression of proprotein convertase subtilisin/kexin type 9 (PCSK9).
  4. Potent activation of peroxisome proliferator-activated receptor alpha (PPAR-α).
Explanation: Omega-3 fatty acids, including icosapent ethyl (a pure form of EPA), reduce triglyceride levels primarily by decreasing hepatic triglyceride synthesis and secretion. One of the key enzymes involved in the final step of triglyceride synthesis is acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT). EPA acts as a poor substrate for and inhibitor of DGAT, thus reducing the liver's ability to produce VLDL particles. While omega-3s may have weak PPAR-α activity, it is not their primary mechanism, unlike fibrates.

Question 14

A patient is considering using an over-the-counter fish oil supplement instead of a prescription omega-3 fatty acid product like icosapent ethyl for managing triglyceride levels of 600 mg/dL. Which of the following represents the most significant clinical limitation of using non-prescription supplements for this indication?

  1. Non-prescription supplements contain only the less effective DHA form of omega-3.
  2. Supplements are typically enteric-coated, which reduces the bioavailability of EPA and DHA.
  3. Over-the-counter products are more likely to cause myopathy when combined with statins.
  4. The lower concentration of active ingredients requires ingesting a large, often impractical number of capsules. (correct answer)
Explanation: When you encounter questions comparing prescription omega-3 products to over-the-counter supplements, focus on the practical differences that affect clinical efficacy rather than theoretical pharmacological distinctions. The most significant limitation of OTC fish oil supplements is their low concentration of active omega-3 fatty acids. Prescription products like icosapent ethyl contain highly concentrated EPA (typically 840-1000mg per capsule), while most OTC supplements contain only 300-500mg of combined EPA and DHA per capsule. For a patient with triglycerides of 600 mg/dL, effective treatment typically requires 2-4 grams of omega-3s daily. This means taking 8-12 supplement capsules daily versus 2-4 prescription capsules - a difference that significantly impacts patient adherence and tolerability. Option A is incorrect because many OTC supplements contain both EPA and DHA, and DHA isn't inherently "less effective" - it simply has different therapeutic targets than EPA. Option B misrepresents supplement formulations; enteric coating actually improves tolerability and doesn't reduce bioavailability of omega-3s. Option C incorrectly suggests supplements have higher myopathy risk with statins - this interaction profile is similar between prescription and OTC omega-3 products and is generally minimal. Remember this pattern: when comparing prescription versus OTC formulations of the same drug class, the key clinical difference is usually potency and standardization, not fundamental safety or mechanism differences. High-dose prescription omega-3s exist specifically because achieving therapeutic levels with standard supplements requires impractically large pill burdens.

Question 15

A 65-year-old patient with type 2 diabetes and an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73m² requires therapy for severe hypertriglyceridemia. If a fibrate is chosen, which of the following represents the most appropriate course of action?

  1. Initiate gemfibrozil at the standard dose as it is hepatically metabolized.
  2. Initiate fenofibrate at a reduced dose with close monitoring of renal function. (correct answer)
  3. Avoid all fibrates as they are contraindicated in any stage of chronic kidney disease.
  4. Prescribe fenofibrate at the standard dose but monitor serum creatinine monthly.
Explanation: Fibrates and their active metabolites are primarily eliminated by the kidneys. In patients with moderate chronic kidney disease (CKD), such as an eGFR of 45 mL/min/1.73m², fibrate accumulation can occur, increasing the risk of adverse effects, particularly myopathy. Fenofibrate can be used cautiously in patients with an eGFR between 30 and 59 mL/min/1.73m², but requires a dose reduction and careful monitoring of renal function. Gemfibrozil is generally not recommended in patients with moderate to severe CKD.

Question 16

A patient with severe hypertriglyceridemia (triglycerides > 1000 mg/dL) is started on fenofibrate. After 3 months of therapy, their triglycerides decrease to 300 mg/dL and HDL-C increases from 22 mg/dL to 30 mg/dL. However, their calculated LDL-C has unexpectedly increased from 65 mg/dL to 105 mg/dL.

Which of the following mechanisms best accounts for the observed increase in LDL-C in this patient?

  1. Fibrate-induced downregulation of hepatic LDL receptors.
  2. Increased hepatic synthesis of ApoB-100 containing lipoproteins.
  3. Enhanced conversion of VLDL particles to LDL particles via lipoprotein lipase. (correct answer)
  4. Decreased cholesterol esterification by lecithin-cholesterol acyltransferase (LCAT).
Explanation: Fibrates, via PPAR-α activation, increase the synthesis of lipoprotein lipase (LPL). LPL catabolizes triglyceride-rich lipoproteins like VLDL. In patients with very high baseline triglycerides, the rapid breakdown of a large number of VLDL particles leads to an increased production of VLDL remnants and subsequently LDL particles. This flux through the lipolytic cascade can result in a paradoxical increase in LDL-C, even as triglyceride levels fall dramatically.

Question 17

A 70-year-old male on stable warfarin therapy for atrial fibrillation is diagnosed with mixed dyslipidemia. He is initiated on fenofibrate. Two weeks later, his INR is found to be 4.8 (target range 2.0-3.0). Which of the following best describes the interaction leading to this clinical finding?

  1. Fenofibrate induces CYP2C9, leading to faster metabolism of warfarin.
  2. Fenofibrate displaces warfarin from plasma albumin binding sites. (correct answer)
  3. Fenofibrate inhibits the renal tubular secretion of warfarin metabolites.
  4. Fenofibrate increases synthesis of vitamin K-dependent clotting factors.
Explanation: Fibrates are highly protein-bound and can displace other highly protein-bound drugs, such as warfarin, from their binding sites on plasma albumin. This displacement increases the concentration of free, pharmacologically active warfarin in the circulation, potentiating its anticoagulant effect and leading to an elevated INR and increased bleeding risk. Therefore, close monitoring of INR and a potential reduction in warfarin dosage are necessary when initiating fibrate therapy.

Question 18

A patient taking high-dose omega-3-acid ethyl esters is scheduled for an elective knee replacement surgery in two weeks. What is the most appropriate recommendation regarding this medication prior to the procedure?

  1. Continue the medication as it has no effect on hemostasis.
  2. Increase the dose to reduce perioperative inflammatory responses.
  3. Discontinue the medication 5-7 days before surgery due to increased bleeding risk. (correct answer)
  4. Switch to a low-dose aspirin for superior antiplatelet effect.
Explanation: High doses of omega-3 fatty acids (typically >3 g/day) can inhibit platelet aggregation and prolong bleeding time. This effect is thought to be due to competition with arachidonic acid in the cyclooxygenase and lipoxygenase pathways, leading to the formation of less potent thromboxane A3 and prostaglandin I3. To minimize the risk of perioperative bleeding, it is often recommended to discontinue high-dose omega-3 supplements 5-7 days before elective surgery, allowing time for platelet function to normalize.

Question 19

Apolipoprotein C-III (ApoC-III) is a key regulator of triglyceride metabolism and an inhibitory protein for lipoprotein lipase (LPL). Activation of PPAR-α by fibrates leads to a reduction in hepatic ApoC-III synthesis. What is the direct functional consequence of this reduction in ApoC-III?

  1. Increased hepatic uptake of chylomicron remnants.
  2. Decreased affinity of LDL particles for the LDL receptor.
  3. Disinhibition of lipoprotein lipase, leading to enhanced VLDL catabolism. (correct answer)
  4. Reduced cholesterol ester transfer from HDL to VLDL.
Explanation: ApoC-III is a potent inhibitor of lipoprotein lipase (LPL), the primary enzyme responsible for hydrolyzing triglycerides in VLDL and chylomicrons. By activating PPAR-α, fibrates suppress the gene expression of ApoC-III. The resulting decrease in circulating ApoC-III levels relieves the inhibition on LPL, leading to increased LPL activity and more efficient catabolism of triglyceride-rich lipoproteins. This is a significant, albeit indirect, mechanism by which fibrates lower plasma triglyceride levels.

Question 20

A 55-year-old male with established cardiovascular disease and type 2 diabetes is on maximal-dose statin therapy. His LDL-C is 75 mg/dL, but his triglycerides remain elevated at 380 mg/dL. Based on major cardiovascular outcome trials, which agent would be the most appropriate addition to reduce his residual cardiovascular risk?

  1. Gemfibrozil, due to its potent effect on triglyceride reduction.
  2. An omega-3-acid ethyl ester product (EPA/DHA), as it offers broader lipid benefits.
  3. Fenofibrate, as shown by the ACCORD-Lipid trial to benefit all diabetic patients.
  4. Icosapent ethyl, which has demonstrated cardiovascular event reduction in this population. (correct answer)
Explanation: When you encounter a patient with residual cardiovascular risk despite optimal statin therapy, you need to consider evidence-based add-on therapies that have proven cardiovascular outcomes, not just lipid-lowering effects. This patient represents a classic scenario: established cardiovascular disease, diabetes, well-controlled LDL-C on statin therapy, but persistent hypertriglyceridemia. The key is identifying which agent has demonstrated actual reduction in cardiovascular events in major outcome trials for this specific population. Icosapent ethyl (option D) is correct because the REDUCE-IT trial specifically demonstrated a 25% reduction in major adverse cardiovascular events in patients exactly like this one—those with established cardiovascular disease or diabetes, on statin therapy, with triglycerides 135-499 mg/dL. This purified EPA formulation showed clear cardiovascular benefit beyond triglyceride reduction. Option A (gemfibrozil) is problematic because it significantly increases statin levels, raising myopathy risk, and lacks robust cardiovascular outcome data in the statin era. Option B (omega-3 EPA/DHA combinations) sounds reasonable but multiple trials including VITAL and STRENGTH failed to show cardiovascular benefits. Option C (fenofibrate) misrepresents ACCORD-Lipid, which actually showed no overall cardiovascular benefit in diabetic patients, despite triglyceride lowering. Remember this pattern: for pharmacology questions about cardiovascular risk reduction, prioritize agents with proven outcomes in major trials over those that simply improve surrogate markers like lipid levels. The evidence hierarchy matters more than theoretical mechanisms.